E-Book, Englisch, 254 Seiten
Sharma / Alam Mucosal Vaccine Delivery Systems: The Future of Immunization (Part 2)
2. Auflage 2025
ISBN: 979-8-89881-024-5
Verlag: De Gruyter
Format: EPUB
Kopierschutz: 0 - No protection
E-Book, Englisch, 254 Seiten
ISBN: 979-8-89881-024-5
Verlag: De Gruyter
Format: EPUB
Kopierschutz: 0 - No protection
Continuing on the groundbreaking discussion on next-generation mucosal vaccines, Mucosal Vaccine Delivery Systems: The Future of Immunization - Part II highlights innovations that redefine preventive healthcare and immunotherapy. By integrating research insights with translational applications, this volume examines the latest progress in mucosal delivery routes, immunological responses, and technological advances that enhance vaccine stability, efficacy, and accessibility . The book draws on global expertise to explore nasal, oral, pulmonary, and urogenital vaccination systems, offering perspectives on formulation strategies, immune modulation, and delivery optimization. It also discusses evolving regulatory frameworks, emerging biotechnological tools, and the socioeconomic impact of widespread mucosal vaccine adoption. Key Features Examines advances in mucosal vaccine platforms and immune mechanisms. Explores innovative delivery routes enhancing patient compliance and protection. Addresses challenges in formulation, stability, and large-scale production. Evaluates regulatory and commercial trends shaping vaccine deployment. Highlights translational research bridging laboratory discovery and clinical application.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Regulatory Considerations for Mucosal Vaccination
Shivkanya Fuloria1, Sunita2, Ashish3, Shaweta Sharma4, Akhil Sharma5, *
Abstract
Mucosal vaccination has the potential to revolutionize immunization and has several benefits over other conventional parenteral vaccination routes, including enhanced mucosal immune responses and ease of administration. However, the regulatory environment for mucosal vaccines is complex and diverse, necessitating a detailed understanding of the requirements for their development, approval, and deployment. This section offers an in-depth examination of how a regulatory framework is constituted around mucosal vaccinations. This chapter starts with an overview of mucosal vaccination and its importance in the fight against infectious diseases. It proceeds to explore various regulatory policies provided by leading regulatory agencies, which include the Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO). It gives a comprehensive look into what makes the control of mucosal vaccines different from others, such as immunological mechanisms, administration routes that are best, formulation stability, and safety assessment. The chapter presents critical insights and best practices for navigating the regulatory landscape effectively through analysis of diverse case studies representing successful regulatory approval processes for mucosal vaccines. Also, it talks about future perspectives on emerging technologies, regulatory adaptations to accommodate evolving scientific advancements, and the necessity for global collaboration to accelerate the development and regulatory approval of mucosal vaccination strategies. The main purpose of synthesizing contemporary regulatory knowledge and giving practical advice in this chapter was to create a useful tool for investigators, producers, and regulatory officials who are working on mucosal vaccines. In the long run, this work will help advance global public health programs.
* Corresponding author Akhil Sharma: R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India; E-mail: xs2akhil@gmail.com
INTRODUCTION
Mucosal immunization is a novel form of vaccination that has numerous advantages over traditional injectable vaccines. It induces potent immune responses at the same sites on the mucosa, such as respiratory, gastrointestinal, and genitourinary tracts, where pathogens commonly invade the system. This affords an emergency response to infection-targeting pathogens before they become systematic [1].
An important advantage of mucosal immunization is its potential to result in local and systemic immune responses. Consequently, these immunizations not only prevent initial infections but also confer systemic protection, thus improving the overall efficacy of vaccines. For microbes that can invade both mucosal and systemic tissues, such double immunity guarantees total protection against numerous infectious agents [2].
Furthermore, mucosal vaccines provide additional benefits that can help to increase immunization coverage and public health outcomes. Patients with needle aversion or fear of needles are more likely to be interested in this method of injection without a needle or painful one. As a result, higher rates of vaccination and improved neighborhood security against the spread of infectious diseases may occur. Again, ease of administration and the possibility for self-administration in certain instances make mucosal vaccines the ideal means of reaching remote regions or areas with limited healthcare services [3].
Moreover, the adaptability of mucosal vaccine systems enables the creation of vaccines for an array of pathogens, including parasites, bacteria, and viruses. These vaccines can be given through several noninvasive alternatives, such as oral tablets, nasal sprays, or aerosols, that do away with the use of needles and syringes, hence minimizing needlestick injuries. This also promotes safety in addition to making possible mass immunization campaigns and hastening world-wide immunization initiatives [4].
On the other hand, the use of mucosal vaccination faces a number of challenges that should be considered and studied continuously. Among the major issues researchers in this area have to deal with are working towards overcoming mucosal barriers, formulating vaccines for stability and effectiveness, and ensuring safety and tolerability. In addition, unlike systemic responses, mucosal immune responses might require tailored approaches to vaccine design and evaluation [5].
Mucosal vaccination has great potential for stopping infectious diseases and for improving public health. Because they use mucosal immunity, these vaccines are a new, effective strategy to keep populations immune from many pathogens. To fully benefit from this aspect of health in the world we are facing today, further research on mucosal immunization and development should be conducted [6].
Importance of Regulatory Considerations
Regulatory considerations are paramount in the development, approval, and deployment of any vaccine, including mucosal vaccines.
Safety
Safeguarding public health, regulatory agencies play a crucial role by ensuring that vaccines, which include mucosal vaccines, meet strict safety standards during their development and deployment. Mucosal vaccines often require extensive evaluation to tackle dangers like local irritation or systemic adverse reactions through innovative delivery modalities or formulations. Regulatory oversight is necessary throughout the preclinical and clinical developmental cycle in order to effectively identify and counteract safety issues [7]. In the preclinical stage, regulatory authorities demand a lot of laboratory testing so as to evaluate the safety profiles of various mucosal vaccine candidates. Such works include determining their potential toxicity, immunogenicity, and pharmacokinetics. There are also experiments carried out on animals in order to examine the biological effects of vaccines and confirm if they would lead to an appropriate immune response without causing harm [8].
When mucosal vaccines are advanced to clinical trials, regulatory oversight becomes even more imperative. Phase I trials are aimed at establishing the safety profile of the virus in a small number of people who will get it for experimental purposes; following this, it is given to them in different doses so that they can determine which dose is the best. In phase II, the number of individuals being studied rises so as to evaluate safety and immunogenicity within a bigger cohort, thereby providing more information about risks and benefits [9]. In phase III trials, the regulatory body looks at the safety data collected from a large and diverse population to confirm that the vaccine is safe as well as effective. Adverse events are reported and analyzed in considerable detail in order to identify unexpected reactions or patterns. Besides, regulators evaluate if the vaccine
prevents infection or disease by setting efficacy thresholds for product approval purposes.
During the regulatory review process, manufacturers must comply with GMP to maintain uniformity and purity of mucosal vaccines. In order to confirm conformity with set standards, Regulatory agencies inspect manufacturing facilities and scrutinize production processes [10]. This is because it is necessary to continue monitoring the effectiveness and safety of mucosal vaccines in the long term, even after regulatory authorities have approved them. Governments then create means of monitoring adverse events after immunization (AEFI) and carry out pharmacovigilance work designed to detect early warning signs for safety problems. Evaluating the safety of mucosal vaccines and protecting public health is the pivotal role that regulatory agencies play. Their stringent...
